Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769892 | 0.88 | RAB9A (0.52) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6769856 | 0.86 | RAB9A (0.54) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6766186 | 0.86 | MEN1 (0.51) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL7687336 | 0.84 | MAOB (0.52) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6765884 | 0.84 | RAB9A (0.48) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL7686490 | 0.84 | MAOB (0.49) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6769840 | 0.84 | KMT2A (0.54) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6769382 | 0.83 | MAPT (0.49) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6776420 | 0.83 | RAB9A (0.48) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL6766612 | 0.83 | L3MBTL1 (0.51) | RAB9ANPC1KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | F2R 147/4885RAB9A 1539/4885NPC1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.